Life Sciences

Why 2021 will be a pivotal year for life sciences patents in China

Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system

Why 2021 will be a pivotal year for life sciences patents in China
Hot tech sectors power Korean patent growth in 2020
21 Jan 2021

Hot tech sectors power Korean patent growth in 2020

KIPO says users turned crisis to opportunity, recording a big increase in IP creation

Six life sciences IP dealmaking trends to watch out for in 2021
19 Jan 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

Latest

View all
14 Jan 2021

New Brazilian biotech patent examination guidelines a “missed opportunity”

While boosting transparency, the many difficulties faced by life sciences innovators when applying for protection in the country are not addressed Read more

12 Jan 2021

Newly-passed Orange Book law leaves the big questions unanswered

Clearing up remaining uncertainties over FDA patent listings will be the subject of intense debate in the US over coming months Read more

7 Jan 2021

Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers

A US patent transparency amendment has mixed implications for the strategies pursued by biologics copycat producers Read more

5 Jan 2021

Generic drug pathway could be “decimated” by recent CAFC judgment

Skinny-label drugs to face greater litigation dangers unless recent decision is overturned, warn 57 academics Read more

News

View all
18 Dec 2020

Japan’s leading corporate IP departments revealed

The country's Asia IP Elite made some big strategic shifts in 2020 as they weathered an unprecedented year Read more

17 Dec 2020

China’s top in-house IP teams revealed

In a year marked by resilience, Chinese IP giants are pushing to close the gap with overseas competitors Read more

14 Dec 2020

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

Analysis

View all
30 Dec 2020

The biggest life sciences IP stories of 2020

Although the year was dominated by the response to covid-19, there were other major developments as well Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

17 Dec 2020

What you need to know about post-Brexit changes to the UK’s SPC system

Failures to update IP management following the New Year could be costly for life sciences businesses Read more

16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

IP Market news highlights

IAM’s biggest spring reads Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more